Gamma-Delta T Cells Double Two-Year Survival in Glioblastoma, IN8bio Data Show
INAB is trading near its 52-week low of $0.8 (2.5% above the low) on light trading volume (0.2× avg).
Summary
IN8bio's INB-200/INB-400 programs in newly diagnosed glioblastoma showed a median overall survival of 20.9 months in repeat-dose patients versus 13.2 months for standard of care, a 59% improvement, with median progression-free survival of 13.0 months versus 6.6 months. Half of repeat-dose patients (7 of 14) were alive at two years against 10% (1 of 10) in the control group, and the therapy produced no CRS, ICANS, major infections or treatment-related serious adverse events across up to six doses. The result held despite fewer repeat-dose patients having total surgical resection (43% vs 80% in controls), which strengthens the read. This is the final Phase 1/2 update presented at SNO on November 14, and it lands just eleven days after the Q3 10-Q disclosed a $4.6 million quarterly net loss and $14.0 million of cash that only funds operations through April 2027 with substantial doubt about going concern. The data improve the scientific case for the platform, but the company still needs a partner or financing to advance it, and the existing $2.8 million at-the-market program is small relative to that need. Next hard checkpoint is the cash runway into April 2027 and any partnership or financing announcement before then.
At the time of this announcement, INAB was trading at $0.82 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.9M. The 52-week trading range was $0.80 to $2.73. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.